Getting overwhelmed by the news is an everyday struggle for those wishing to stay in touch with the latest news. Our newsletter should make it easier for those interested in pharmacovigilance regulations, advancement in the relevant use of artificial intelligence, and personal growth. Approaching with care, the same as we provide PV services, we thoughtfully pick articles every month to keep you updated.
As companies adopt AI, many are focused on improving efficiency and productivity—benefits advertised by the AI companies themselves. That focus might be a mistake.
Agreement on the proposed Critical Medicines Act (CMA) represents an important step for boosting the EU pharma sector.
EMA recommendation to update the antigenic composition of authorised COVID-19 vaccines for 2026-2027.
And much more...
EMA recommendation to update the antigenic composition of authorised COVID-19 vaccines for 2026-2027
Questions and answers on periodic safety update report single-assessment (PSUSA): Guidance document for assessors
EMA welcomes the provisional agreement reached by the European Parliament and the Council of the European Union on the proposed Critical Medicines Act (CMA), which represents an important step in strengthening the resilience, security and sustainability of the European Union’s supply of critical medicines.
As companies adopt AI, many are focused on improving efficiency and productivity—benefits advertised by the AI companies themselves. That focus might be a mistake.
Conventional pain management strategies often fall short in addressing the complex needs of older adults with pain. Artificial intelligence (AI) represents a significant potential for advancing personalized, data-driven approaches. This review explores the literature on AI in pain management for older adults, showing trends and existing gaps.
University of Virginia School of Medicine scientists have developed a bold new approach to drug development and discovery that could dramatically accelerate the creation of new medicines.
Agreement on the proposed Critical Medicines Act (CMA) represents an important step for boosting the EU pharma sector.
The biotech industry’s enthusiasm for artificial intelligence (AI) has not disappeared, but the conversation around the technology is becoming more grounded than it was during the first major wave of AI-focused biotech funding.
The European Commission (EC), the Heads of Medicines Agencies (HMA) and EMA have published their first report tracking progress against the EU’s new clinical trial targets. Established in 2025, these targets aim to strengthen the European Union’s (EU) position as a leading destination for clinical research while improving patients’ timely access to innovative medicines.
Pictures used in this newsletter were generated by AI.